

INDEX

Note: Page numbers in *italics* indicate figures;
page numbers followed by t indicate tables.

- Acidosis
 - hyperchloremic, 102
 - renal tubular, 267
- Acquired immunodeficiency syndrome (AIDS), 73t
- Actonel (risedronate), 176t, 179
- Addison's disease, 127t, 130
- Adolescence
 - dietary calcium and vitamin D in, 201, 205
 - hypercalcemia in, 73t
 - physical activity in, 201-202
- Adrenal crisis, 72t, 79, 83t
- Adynamic bone disease, 183
- Age/aging
 - bone density and, 35-36
 - bone growth and, 26
 - bone remodeling and, 27
 - osteoporosis and, 197, 200t, 201-202
 - vitamin D deficiency and, 205-206, 235-236
- Albright's hereditary osteodystrophy, 127, 128t, 129
- Alcohol abuse, 208
- Alendronate (Fosamax)
 - adherence to regimen of, 227
 - cost effectiveness of, 240
 - dosage of, 176t, 177-178
 - indications for, 223t, 228
 - results using, 228, 247t
 - side effects of, 178
- Alkaline phosphatase, 220
 - bone specific, 32, 33
 - deficiency of, 163. See also *Hypophosphatasia*.
 - in serum, in Paget's disease, 173
- Alkalosis, 117
- Alopecia, 127t
- Alphacalcidol, 122
- Aluminum toxicity
 - osteomalacia and, 164
 - renal osteodystrophy and, 189-190

Alzheimer's disease, 226
 Anabolic steroids, 237
 Androgen, for females, 204, 237
 Anemia
 pernicious, 127t, 130
 in primary hyperparathyroidism, 100t, 102
 Anorexia nervosa, 203
 Antacids, phosphate-binding, osteomalacia and, 164
 Anticonvulsants, 209
 Apoptosis, of osteoclast, 37
 Appendicular skeleton, cortical bone in, 16
 Aredia (pamidronate), 229
 for hypercalcemia, 85t, 87, 92-93, 93t
 for Paget's disease, 176t, 178
 Arrhythmia, ventricular, 91
 Arthritis, rheumatoid, 73t
 Asplenia, 127t

Berylliosis, 73t
 Biological markers. See *Bone markers*.
 Bisphosphonates
 action mechanisms of, 227
 for hypercalcemia, 85t, 87-88
 for osteoporosis, 223t, 227-229, 236t, 238, 247t, 248
 for Paget's disease, 175, 176t, 177-178, 180
 for primary hyperparathyroidism, 108, 113
 Bleeding, gastrointestinal, 74
 Blomstrand's chondrodysplasia, 50
 Blood, mineral metabolism in, calcitonin and, 58t
 Body weight, osteoporosis and, 206-207
 Bone
 brittle, 282-283
 calcium removal from, 15
 cancellous, 99
 cortical
 composition of, 16
 percent of, in skeleton, 16
 remodeling of, 26-27
 turnover of, 16
 formation of
 biological markers of, 31t, 32, 33
 osteoblastic, 48
 PTH effects on, 48

Bone (*continued*)
 growth of, 17, 26
 hungry. See *Hungry bone syndrome*.
 mineral phase of, 16, 18t
 organic phase of, 16, 18t
 pain in, 210t, 211
 in primary hyperparathyroidism, 99, 100t, 101, 218
 proteins in, 19t
 size of, race/ethnicity and, 215
 structure of, 15-18, 17, 18t-21t, 20-23, 24t-25t, 26
 trabecular
 consistency of, 16
 locations of, 16
 in osteoporosis, 197
 percent of, in skeleton, 16
 remodeling of, 27
 turnover of, 16
 vitamin D effects on, 62
 Bone cells, 20-23, 21t, 24t, 25, 26. See also specific cell type, eg *Osteoblast*.
 Bone densitometry
 to diagnose osteoporosis, 213, 214t, 215-218
 to measure osteoporosis therapy, 217-218
 in primary hyperparathyroidism, 101, 218
 recommended frequency of, 218
 Bone markers
 abnormal, 220
 accuracy of, 219
 application and value of, 35t, 219-220
 of bone metabolism, 30-31, 31t, 32, 33-35, 35t
 commercial availability of, 31, 33
 of formation, 31t, 32, 33
 fracture risk assessment with, 221-222
 to monitor therapy, 220-221
 predictive value of, 30, 221
 of resorption, 31t, 33-35
 in serum and/or urine, 32
 Bone marrow transplantation, 282
 Bone mass
 acquisition of, in lifetime, 16
 peak of, 16, 17
 gender and, 201-202

Bone mass, peak of (*continued*)
 genetic factors in, 207
 osteoporosis and, 198, 199, 201-202

Bone Mass Measurement Act of 1998, 218

Bone matrix, 15, 17, 20t

Bone metabolism, 15, 28
 bone markers in, 30-31, 31t, 32, 33-35, 35t
 growth, modeling, and remodeling in, 17, 26-27, 28, 29t
 regulatory factors in, 20t, 27, 29t, 30
 skeletal assessment in, 35-36

Bone mineral density, 16, 18, 18t. See also
Calcium phosphate; Hydroxyapatite crystals; Mineralization.
 calcitonin and, 58t
 fractures and, 198, 199, 215, 222, 224
 homeostasis and, 15
 measurement of
 indications for, 213, 215
 techniques for, 213, 214t
 ultrasonic, 216-217
 in osteoporosis, 100t, 196, 196t, 201-202, 238-239, 246
 in primary hyperparathyroidism, 99, 100t
 T-score in, 195-196, 196t, 216
 World Health Organization recommendation for, 216
 Z-score in, 216

Bone morphogenetic proteins, 19t, 29t
 in bone metabolism, 27, 30

Bone remodeling
 in adult, 16
 stages of, 26

Bone resorption. See also *Osteoporosis.*
 biological markers of, 31t, 32, 33-35
 cytokines increasing, 20t
 inhibition of, in hypercalcemia treatment, 85t, 86-88
 osteoclasts in, 23t, 36-37
 in primary hyperparathyroidism, 99, 100t, 101, 218
 PTH and, 48
 rate of, in Paget's disease, 170
 recalcification after, 109, 109t-110t

Bone-lining cells, 23, 26

Bone-specific alkaline phosphatase, 32, 33, 220

Breast cancer, 226

Brittle bone disease, 282-283

Brown tumors, 99, 100t

Brucellosis, 73t

Calcifediol (Calderol), 123t

Calcification, extraskelatal, 183, 185, 186

Calcijex. See *Calcitrol* (Calcijex, Rocaltrol).

Calcimar. See Calcitonin (Calcimar, Miacalcin) therapy.

Calcimimetics
 action mechanisms of, 46
 for primary hyperparathyroidism, 108, 113
 for renal osteodystrophy, 190

Calcitonin
 disorders of, 204
 functions of, 53-54
 genetic expression of, 56-57
 mineral metabolism and, 58t
 in multiple endocrine neoplasia, 142-143
 in osteoclast regulation, 24t
 serum calcium imbalance and, 64
 structure of, 54

Calcitonin disorders, osteoporosis and, 204

Calcitonin gene-related peptide, structure
 and functions of, 54, 56

Calcitonin therapy (Calcimar, Miacalcin)
 for hypercalcemia, 85t, 86-87, 92-93, 93t
 for osteoporosis, 223t, 229-230, 236t, 238, 247t
 for Paget's disease, 54, 175, 176t, 177, 180

Calcitonin (Calcimar, Miacalcin) therapy, for
 hypercalcemia, 85t, 86-87, 92-93, 93t

Calcitrol (Calcijex, Rocaltrol)
 for hypoparathyroidism, 123t, 126
 for osteomalacia, 165
 for osteoporosis, 244, 244t, 247t, 248
 for renal osteodystrophy, 189, 189t, 192

Calcium
 dietary
 in adolescence, 201
 daily recommendations for, 206, 206t
 osteoporosis and, 204-206, 206t, 238
 intestinal absorption of, vitamin D in, 59, 62
 malabsorption of, osteomalacia and rickets from, 156, 157t

Calcium (*continued*)
 pathway to skeleton, 36
 urinary, as resorption marker, 35
 Calcium absorption
 in osteomalacia and rickets, 85t, 88
 reduction of, in hypercalcemia treatment, 85t, 88
 Calcium metabolism, 44t
 calcitonin in, 53-54, 64
 glucocorticoids and, 63
 hormones and, 63
 insulin and, 63
 intracellular vs. extracellular, 43
 ionized, 43-44
 PTH in, 44-50, 46t, 49t, 64
 PTHrP in, 50-52, 51t, 53t
 vitamin D in, 55, 58t, 58-59, 59, 61t, 62-64, 63t
 Calcium phosphate, amorphous, 18
 Calcium therapy
 administration routes in, 131-132
 commercial preparations of, 124, 124t
 dosages of, 131-132, 132t, 134
 for hypoparathyroidism, 122, 124t, 124-126
 for osteomalacia, 165
 for osteoporosis, 233-235, 238, 248
 Calcium-regulating hormones, osteoporosis and, 204
 Calcium-sensing receptor
 genetic abnormalities of, 45-46, 46t
 familial hypocalciuric hypercalcemia and, 78
 hypoparathyroidism and, 121t
 PTH secretory regulation by, 45-47, 46t
 structure of, 45
 Calciuresis, 84-86, 85t, 92, 93t
 Calderol (calcifediol), 123t
 Cancellous bone, 99
 Cancer cells, vitamin D effects on, 61t
 Candidiasis, 73t
 mucocutaneous, 127t, 130
 Canine distemper virus, 169
 Cardiovascular system
 estrogen therapy and, 226
 in hypocalcemia, 118t
 Cat-scratch disease, 73t

Central nervous system, vitamin D effects on, 61t
 Children, rickets in, 155
 hypophosphatemia and, 162
 Chloroquine, 85t, 90
 Cholecalciferol synthesis, 55, 123t, 126
 Cholelithiasis, 127t
 Chvostek's sign, 112t, 117, 118t, 133
 Coccidioidomycosis, 73t, 83t
 Collagen, 16, 18t
 biosynthesis disorders in, 282-283
 as bone marker, 32, 33
 Collagen peptides, as resorption markers, 32, 33-34
 Colle's fracture, 195-196
 Colony-stimulating factors
 bone resorption and, 20t, 30
 in hypercalcemia of malignancy, 76, 77, 77t
 osteoclast precursors and, 23
 osteoclast regulation by, 24t
 Coma, 100t, 102
 Connective tissue disease, 209
 Cortical bone. *See Bone, cortical.*
 Coupling, 27
 Crohn's disease, 73t
 Cushing's syndrome, 240
 Cutaneous lichen amyloidosis, 146t
 Cytokines
 in bone matrix, 15, 17, 20t
 bone metabolism regulation by, 20t, 27
 bone resorption and, 20t, 23
 in osteoclast regulation, 24t
 Dehydration, 72t, 74
 Dehydroepiandrosterone, 237
 Densitometry. *See Bone densitometry.*
 Dental hypoplasia, 131
 Deoxyypyridinoline, as resorption marker, 32, 34
 Diabetes mellitus
 hypophosphatemia and, 162
 insulin-dependent, 127t, 130
 osteoporosis and, 209
 Dialysis, 72t
 Didronel (etidronate), 176t, 228
 DiGeorge syndrome, 121t

1,25-Dihydroxyvitamin D. See also *Vitamin D entries*.

renal production of
in hypercalciuria, 266
in hypocalcemia, 119
PTH and, 47-48
regulation of, 58t
in renal osteodystrophy, 183

Dihydrotachysterol
for hypoparathyroidism, 122, 126
for renal osteodystrophy, 189, 189t

24,25-Dihydroxyvitamin D. See *Vitamin D entries*.

Diuretics, thiazide. See *Thiazide diuretics*.

Ectodermal dystrophy, 127t

Edecrin (ethacrynic acid), 85t, 86

Edidronate bisodium, 164

Ellsworth-Howard test, 129

Endocrine neoplasia, multiple. See *Multiple endocrine neoplasia*.

Epidermal growth factor, 30

Epithelium, vitamin D effects on, 61t

Ergocalciferol, 55, 123t, 126

Estradiol transdermal patch, 225

Estratab, 223t, 225

Estrogen receptor modulators, selective (SERMs).
See *Raloxifene (Evista)*.

Estrogen therapy, 217-218

commercially available products for, 223t, 225

in hypercalcemia treatment, 85t, 90

in males, 204, 237

for osteoporosis prevention and treatment, 202, 217-218,
222, 223t, 224-227, 236t, 238, 244t, 247t, 248

for postmenopausal primary hyperparathyroidism, 108

predicting response to, bone markers in, 221

side effects of, 226-227

Ethacrynic acid (Edecrin), 85t, 86

Ethiofos (WR-2721), 85t

Ethnicity. See *Race/ethnicity*.

Etidronate (Didronel), 176t, 228

Evista (raloxifene)

for osteoporosis, 223t, 231-232, 247t

for primary hyperparathyroidism, 108

Exercise, osteoporosis and, 201-202, 208-209

Extraskeletal calcification, in renal osteodystrophy, 183,
185, 186

Falling

factors predisposing to, 238t

procedures to minimize, 239t

Familial hyperparathyroidism

hypercalcemia and, 72t

pathogenesis of, 84, 98

Familial hypocalciuric hypercalcemia

diagnosis of, 79, 83t, 102

hypercalcemia and, 72t

primary hyperparathyroidism and, 78-79

Familial hypoparathyroidism, 121t

Familial medullary thyroid carcinoma, 146, 146t

Family history, osteoporosis risk and, 198

Fanconi's syndrome, 157t, 163

Femur, in Paget's disease, 170, 171t

Fetus, PTHrP in, 50, 51t

Fibroblast growth factors, 30

Fibrous dysplasia, 283-284

Fleet Phospho-Soda, 279t

Fluorides, 233, 236t

Fosamax (alendronate). See *Alendronate (Fosamax)*.

Fractures

alcohol abuse and, 208

body weight and, 207

cigarette smoking and, 208

gonadal steroids and, 202-203

heredity and, 207

in osteopenia, 196

in osteoporosis

bone mineral density and, 198, 199, 215, 222, 224

death from, 210-211

pharmacologic prevention of, FDA standards for, 222, 224

sites of, 195-197, 210t, 210-211

prevention of. See *Falling; Osteoporosis, prevention and treatment of*.

in primary hyperparathyroidism, 99, 100t

Furosemide (Lasix), 85t, 86, 93t

Gait, in vitamin D disorder, 158
 Gallium nitrate (Ganite), 85t, 90
 Gamma carboxyglutamic acid, bone proteins containing, 19t
 Ganglioneuromatosis, 138t
 Gastrointestinal disease, osteoporosis and, 209
 Gastrointestinal tract
 mineral metabolism in, 58t
 in primary hyperparathyroidism, 100t, 101
 PTH effect on, 48
 Gender
 osteoporosis and, 197, 200t, 201-202
 peak bone mass and, 16
 Giant cell tumors, 173
 Glucocorticoids
 calcium metabolism and, 63
 in hypercalcemia treatment, 85t, 89-90
 osteoporosis induced by, 209, 240-244, 241t, 244t
 therapeutic, bone densitometry in, 218
 Glycoproteins, in bone, 19t
 Glycosaminoglycan, in bone proteins, 19t
 Gonadal steroids, for osteoporosis, 200t, 202-204, 237
 Granulomatous disease, 73t, 82, 83t
 Graves' disease, 127t
 Growth, of bone, 26
 Growth factors
 in bone matrix, 15, 17, 20t
 bone metabolism regulation by, 20t
 Growth hormone therapy, 237

 Harrison's groove, 158, 166
 Haversian canal, 22
 Height, loss of, 210
 Hemocheomotosis/siderosis, 121t
 Hepatitis, chronic active, 127t
 Hip fracture
 from falls
 factors predisposing to, 238t
 procedures to minimize, 239t
 gender and, 197
 in osteoporosis, 195-197, 210t, 210-211
 Hirschsprung's disease, 146t
 Histioplasmosis, 73t

Hormones, bone metabolism regulation by, 27, 29t, 30
 Howship lacuna, 23
 Hungry bone syndrome
 causes of, 109, 131
 diagnosis of, 109
 differential diagnosis of, 110t
 hypoparathyroidism and, 121-122
 pathogenesis of, 109
 treatment of, 111t, 131-133, 132t
 Hydroxyapatite crystals, 16, 18t
 Hydroxyproline, urinary, as resorption marker, 35
 Hyperalbuminemia, 72t
 Hypercalcemia
 causes of, 71, 72t-73t, 91-92
 adrenal insufficiency as, 72t, 79, 83t
 endocrinopathy as, 72t, 77-79, 83t
 granulomatous disease as, 73t, 82, 83t
 hyperparathyroidism as
 primary, 71, 72t, 74, 77-78, 83t, 97-98
 tertiary, 81-82, 83t
 hyperthyroidism as, 78
 immobilization as, 73t, 82, 91
 lithium therapy as, 72t, 78, 80
 malignancy as, 72t, 75-77, 76, 77t, 83t, 92, 97
 milk-alkali syndrome as, 72t, 81
 PTH as, 48
 PTHrP as, 52
 renal disease as, 73t, 81
 thiazide diuretics as, 72t, 78-79
 vitamins D and A as, 72t, 80
 complications from, 74
 differential diagnosis of, 72t-73t, 82, 83t
 familial hypocalciuric. See *Familial hypocalciuric hypercalcemia*.
 calcium sensor abnormality in, 46, 46t
 humoral, 72t, 77t
 idiopathic, of infancy, 72t
 infantile, 73t
 levels of PTH, vitamin D, and calcitonin in, 64
 of malignancy, 71
 diagnosis of, 83t
 incidence of, 97
 pathogenesis of, 75-77, 76, 77t, 92

Hypercalcemia (*continued*)

- serum calcium level in, 71, 103
- signs and symptoms of, 71, 74, 92
- treatment of, 92, 93t
 - bisphosphonates in, 85t, 87-88
 - calcimimetic drugs in, 88
 - calcitonin in, 54, 85t, 86-87, 92-93, 93t
 - calciuresis in, 84t-85t, 84-86, 92, 93t
 - diagnosis of underlying disease in, 84, 84t-85t, 89, 93t
 - dialysis and EDTA in, 85t, 91
 - glucocorticoids in, 85t, 89-90
 - hormones in, 85t, 90
 - hydration in, 93t
 - inhibition of bone resorption in, 85t, 86-88, 93t
 - oral phosphorus in, 90
 - patient mobilization in, 91
 - reduction of calcium absorption in, 85t, 88
 - volume expansion and calciuresis in, 84-86, 85t
- ventricular arrhythmia in, 91

Hypercalciuria

- definition of, 265
- etiology and pathogenesis of, 265-267, 266t
- idiopathic, 265
- predisposition to, 265
- in primary hyperparathyroidism, 99, 100t
- signs and symptoms of, 267, 268
- treatment of, 267-268, 269t

Hyperchloremic acidosis, 102

Hypergammaglobulinemia, 72t

Hypergonadotropic gonadism, 127t

Hyperlipidemia, 72t

Hypermagnesmia

- pathogenesis of, 275, 276t
- signs and symptoms of, 276
- treatment of, 277-278

Hyperparathyroidism

- bone remodeling in, 27
- familial
 - hypercalcemia and, 72t
 - pathogenesis of, 84, 98
- neonatal severe, 72t
 - calcium sensor abnormality in, 46, 46t

Hyperparathyroidism (*continued*)

- osteoclastic bone resorption in, 48
 - primary
 - biochemical features of, 97
 - clinical features of
 - gastrointestinal, 100t, 101
 - in nervous system, 100t, 102
 - renal, 99, 100t
 - skeletal, 99, 100t, 101, 218
 - complications of, 100t, 102
 - diagnosis of, 98, 112-113
 - etiology and pathogenesis of, 98-99, 112
 - genetics of, 98
 - hypercalcemia and, 71, 72t, 74, 77-78, 83t, 97-98
 - incidence of, 97
 - laboratory findings in, 102-103
 - medical history in, 97
 - in multiple endocrine neoplasia, 138t-139t, 140, 143-144
 - postmenopausal, 108
 - screening for, 98-99
 - treatment of
 - medical, 108, 113
 - surgical, 104-107, 105t-107t, 113
 - secondary
 - in osteomalacia and rickets, 160
 - osteoporosis and, 197
 - renal osteodystrophy and, 184, 185, 186
 - tertiary
 - hypercalcemia and, 81-82, 83t
 - renal osteodystrophy and, 185, 186
 - transient, 98
- ### Hyperparathyroidism-jaw tumor syndrome, 98
- ### Hyperphosphatemia
- hypocalcemia and, 119, 131
 - pathogenesis of, 273, 274t
 - signs and symptoms of, 276, 280
 - treatment of, 277, 278t
- ### Hypertension, in primary hyperparathyroidism, 100t, 102
- ### Hyperthyroidism, hypercalcemia and, 78
- ### Hypoalbuminemia, 117

Hypocalcemia
 acute. See also *Hungry bone syndrome*.
 causes of, 131, 133-134
 treatment of, 131-133, 132t
 causes of
 hypoalbuminemia as, 117, 133
 renal failure as, 117, 119-120, 133
 differential diagnosis of, 119
 laboratory findings in, 117
 levels of PTH, vitamin D, and calcitonin in, 64
 neuromuscular excitability in, 117
 after parathyroidectomy
 differential diagnosis of, 110t
 mechanisms of, 108-109, 109t
 treatment of, 109, 111, 111t-112t
 pathophysiology of, 117
 signs and symptoms of, 117, 118t
 treatment of, in renal failure, 119-120
 Hypocalciuric hypercalcemia
 familial. See *Familial hypocalciuric hypercalcemia*.
 in thiazide and lithium therapy, 78
 Hypogonadal disorders, 204
 Hypogonadism, 127t
 Hypomagnesemia
 hypoparathyroidism in, 121t, 125, 134
 pathogenesis of, 275, 275t
 signs and symptoms of, 276
 treatment of, 132-133, 133t, 277
 Hypoparathyroidism. See also *Pseudohypoparathyroidism*.
 causes of, 120-122, 121t
 hypomagnesemia as, 121t, 125, 134
 neck surgery as, 120, 121t, 125
 familial, 121t
 idiopathic, 126, 127t
 during menses, 125
 polyendocrine deficiency disorders associated with, 127t,
 130-131, 134
 primary, pseudohypoparathyroidism with, 129
 treatment of
 calcium and vitamin D in, 122, 123t, 124-126
 PTH in, 125

Hypophosphatasia, 73t
 osteomalacia and rickets in, 157t, 163
 Hypophosphatemia
 causes of, PTH as, 48
 osteomalacia and rickets in, 156, 157t, 162
 pathogenesis of, 273, 274t
 signs and symptoms of, 277t, 280
 treatment of, 277, 279t
 Hypophysitis, 127t
 Ibandronate, 87
 Immobilization
 bone resorption and, 170
 hypercalcemia and, 73t, 82
 osteoporosis and, 200t, 209
 Immune system, vitamin D effects on, 61t, 62-63
 Indomethacin, for hypercalcemia, 85t
 Infancy. See also *Neonate*.
 idiopathic hypercalcemia of, 72t
 Insulin, calcium metabolism and, 63
 Insulin-like growth factor(s)
 bone formation and, 30
 osteoporosis and, 207
 Interferons, in hypercalcemia of malignancy, 76, 77, 77t
 Interleukin(s)
 bone resorption and, 20t, 30
 in hypercalcemia of malignancy, 76, 76-77, 77t
 osteoclast precursors and, 23
 osteoporosis and, 207
 Interleukin 6, Paget's disease and, 169
 Jansen's chondrodysplasia
 hypercalcemia and, 73t
 PTH/PTHrP receptor in, 50
 Jaw tumor, hyperparathyroidism with, 98
 Keratoconjunctivitis, 127t
 Ketoconazole, 85t
 Kidney. See also *Renal entries*.
 1,25-dihydroxyvitamin D production in, PTH and, 47-48
 mineral metabolism in, calcitonin and, 58t
 PTH effects on, 47-48

Kidney (*continued*)
 vitamin D effects on, 62, 158t
 vitamin D metabolism in, 55, 58, 58t
 Kidney stones. See *Nephrolithiasis*.
 Klinefelter's syndrome, 204
 K-Phos, 279t

Laryngeal cancer surgery, 120, 121t
 Lasix (furosemide), 85t, 86, 93t
 Leprosy, 73t
 Lithium therapy, 72t, 78, 80
 Liver
 vitamin D disorders and, 158t
 vitamin D metabolism in, 55
 Liver disease, advanced chronic, hypercalcemia in, 73t
 Looser's zones, 160
 Low-density lipoprotein cholesterol, raloxifene and, 231
 Luteinizing hormone-releasing hormone, osteoporosis and, 202

Magnesium
 intracellular, PTH secretion and, 47
 skeleton as reservoir for, 36
 Magnesium abnormalities. See also *Hypermagnesmia*;
Hypomagnesmia.
 signs and symptoms of, 276, 280
 treatment of, 277-278

Malignancy
 hypercalcemia of. See *Hypercalcemia, of malignancy*.
 osteoporosis and, 209
 PTHrP in, 50, 52

Manganese, hypercalcemia and, 72t, 77t
 Marfanoid habitus, 138t, 145
 Mast cells, in bone resorption, 23
 McCune-Albright syndrome, 284
 Measles virus, 169
 Medullary thyroid carcinoma
 calcitonin as tumor marker in, 54, 141
 diagnosis of, 142
 genetics of, 145-146
 in multiple endocrine neoplasia, 138t, 141-142, 142t
 products secreted by, 144t

Menopause
 osteoporosis after, 197, 203
 peak bone mass after, 16
 Menses, hypoparathyroidism during, 125
 Mesenchyme, 22
 Miacalcin (calcitonin-salmon). See *Calcitonin*
 (*Calcimar, Miacalcin*) therapy.
 Milk-alkali syndrome, 72t, 81, 84
 Milkman's syndrome, 160
 Mineral phase of bone, 16, 18t. See also *Bone*
mineral density.
 Mineralization, 36
 conditions favorable for, 18, 20
 location of, 18
 osteoblasts in, 22
 in osteomalacia and rickets, 155-156, 166
 vitamin D and, 61t, 62

Mithracin (plicamycin)
 for hypercalcemia, 85t, 91
 for Paget's disease, 175

Mobilization of patient, 85t, 91
 Mucosal neuroma, multiple, 138t, 144-145
 Multiple endocrine neoplasia
 cell types involved in, 137
 classification of, 137, 146t
 clinical features and pathogenesis of
 in type 1, 138-141, 139t
 in types 2A and 2B/3, 138t, 141-145, 142t
 components of, 138t, 148
 diagnosis of, 83t, 146-147, 149
 genetic basis of, 145-146, 146t, 148
 glands involved in, 137
 incidence of
 in type 1, 139t
 in types 2A and 2B/3, 142t
 malignant, 148
 primary hyperparathyroidism in, 78, 98
 transmission of, 137
 treatment of, 147-149

Muscle strength
 osteoporosis and, 207
 vitamin D and, 61t

Na⁺/H⁺ antiporter, PTH inhibition of, 48
 National Osteoporosis Foundation, 238-240
 Neck surgery, hypoparathyroidism after, 120, 121t, 125
 Neonate
 hyperparathyroidism in
 severe, 72t
 transient, 98
 hypoparathyroidism in, 121t
 Nephrocalcinosis, 99, 100t
 Nephrolithiasis
 pathogenesis of, 266, 266t
 in primary hyperparathyroidism, 99, 100t
 signs and symptoms of, 267
 stone composition in, 268t
 treatment of, 268-269, 269t
 X-linked recessive, 163
 Nervous system, in primary hyperparathyroidism, 100t, 102
 Neuromuscular excitability, in hypocalcemia, 117
 Neuromuscular system, in hypocalcemia, 118t
 Neutra-Phos, 279t
 Nocardia, 73t
 NPSR 568, 46

 Ogen, 223t
 Organic phase of bone, 16, 18t
 Ossification, intramembranous, 26
 Osteitis deformans. See *Paget's disease*.
 Osteitis fibrosa cystica, 99, 100t
 laboratory tests in, 212t
 in renal osteodystrophy, 183
 renal osteodystrophy and, 184, 185, 186
 Osteoarthritis, 50
 Osteoblast
 functions of, 21-22
 precursors of, 22, 25
 regulation of, 21t
 Osteocalcin
 as bone marker, 32, 33
 vitamin D and, 62
 Osteoclast
 apoptosis of, 37
 in bone resorption, 23, 48
 calcitonin and, 53

Osteoclast (*continued*)
 cellular and molecular biology of, 284
 precursors of, 23, 25
 regulation of, 24t
 Osteocyte, 22-23
 Osteodystrophy
 Albright's hereditary, 127, 128t, 129
 renal. See *Renal osteodystrophy*.
 Osteogenesis imperfecta, 282-283
 Osteogenic sarcoma, 173
 Osteoid mineralization, 18, 29
 Osteomalacia
 clinical manifestations of, 155-156, 158, 166
 differential diagnosis of, 164
 etidronate and, 229
 etiology and pathogenesis of, 156, 157t, 166
 drug-related, 156, 157t, 164
 hypophosphatasia as, 163
 hypophosphatemic disorders as, 162-163
 inherited diseases as, 166-167
 oncogenic, 163
 vitamin D abnormalities as, 160-162
 laboratory findings in, 158, 212t
 pathology of, 155-156
 pseudofractures in, 160
 renal osteodystrophy and, 183-184, 185, 187
 treatment of, 164-165, 167
 x-ray findings in, 159-160
 Osteopenia
 bone densitometry in, 218
 fracture risk in, 196
 Osteopetrosis
 pathophysiology of, 281-282
 treatment of, 282
 types of, 281, 282t
 Osteoporosis. See also *Bone resorption*.
 classification of, 197
 cost of, 196, 239-240
 definition of, 195
 diagnosis of
 bone densitometry in, 213, 214t, 215-218

Osteoporosis, diagnosis of (*continued*)
 bone mineral density in, 100t, 196, 196t, 201-202, 238-239, 246
 bone size in, 215-216
 ultrasonic, 217
 differential diagnosis of, 212t
 etiology and pathogenesis of, 198-199, 199
 falling in
 factors predisposing to, 238t
 procedures to minimize, 239t
 fractures in
 bone mineral density and, 198, 199, 215, 224, 225
 death from, 210-211, 245
 sites of, 195-196, 210t, 210-211, 238, 245
 incidence of, 195-197
 laboratory tests in, 211, 212t
 National Osteoporosis Foundation guidelines in, 238-240
 peak bone mass and, 198, 199, 201-202
 prevention and treatment of, 246
 anabolic steroids in, 237
 bisphosphonates in, 223t, 227-229, 236t, 238, 247t, 248
 calcitonin in, 223t, 229-230, 236t, 238, 247
 calcitrol in, 244, 244t, 247t, 248
 calcium therapy in, 233-235, 238, 248
 dehydroepiandrosterone in, 237
 estrogen in, 202, 217-218, 222, 223t, 224-227, 236t, 238, 244t, 247t, 248
 fluorides in, 233, 236t
 gonadal steroids in, 200t, 202-204, 237
 growth hormone in, 237
 indications for, 222
 pharmacologic, FDA standards for, 222, 224
 phytoestrogens in, 237
 PTH and PTHrP for, 236t, 236-237
 raloxifene in, 223t, 231-232, 236t, 247t, 248
 vitamin D intake in, 204-206, 235-236, 248
 primary, 197
 risk factors for, 196-197, 199-200, 200t
 age and gender as, 197, 200t, 201-202, 238, 245
 alcohol abuse as, 208, 238
 anorexia nervosa as, 203
 calcium-regulating hormones in, 204

Osteoporosis, risk factors for (*continued*)
 cigarette smoking as, 208, 238
 constitutional, 206-207
 decreased gonadal steroids as, 200t, 202-204, 245
 exercise and, 208-209
 heredity/genetics in, 198, 200t, 245
 immobilization as, 200t
 lifestyle as, 207-208, 245
 low bone mineral density as, 200t, 201-202, 238-239
 medications and illness as, 209
 menopause as, 203
 modifiable, 201t, 245
 nutrition and mineral metabolism as, 200t, 204-206, 206t
 race/ethnicity as, 195
 sunlight exposure and, 205
 secondary, 198
 causes of, 240, 241t
 steroid-induced, 240-244, 241t, 244t
 senile, 197
 signs and symptoms of, 210t, 210-211
 T-scores in, 195-196, 196t, 216
 x-ray studies in, 211, 213
 Osteosarcoma, 173, 180
 Ovarian failure, 130

Paget's disease
 alkaline phosphatase as bone marker in, 33
 bone resorption rate in, 170, 173-174
 clinical features of, 171-173, 172t
 complications of, 173, 180
 diagnosis of, 172, 174
 epidemiology of, 169, 180
 etiology and pathogenesis of, 169-170
 familial, 169-170
 focal vs generalized, 169, 179-180
 hypercalcemia in, 73t
 laboratory findings in, 28, 29t, 173-174, 180, 212t
 neurologic manifestations of, 174
 skeletal involvement in, 170, 171t, 179
 treatment of
 bisphosphonates in, 175, 176t, 177-178, 180
 calcitonin in, 54, 175, 176t, 177, 180
 pain management in, 179, 181

- Pamidronate (Aredia), 229
 - for hypercalcemia, 85t, 87, 92-93, 93t
 - for Paget's disease, 176t, 178
- Pancreatic tumors, 138t-139t, 140-141
- Pancreatitis, 100t, 101
- Paracoccidioidomycosis, 73t
- Paramyxovirus, 169
- Parathyroid hormone
 - biologic effects of, 48-49, 49t
 - characteristics of, 44-45
 - disorders of, osteoporosis and, 204
 - excess of, 183
 - immunoassays of, 48
 - metabolism and clearance of, 47-48
 - mineral metabolism and, 49t
 - for osteoporosis, 236t, 236-237
 - protein kinase activation by, 49-50
 - renal 1,25-dihydroxyvitamin D production and, 47-48
 - secretory regulation of
 - by calcium sensor, 45-47, 46t
 - hypercalciuria and, 266
 - by intracellular magnesium, 47
 - by serum phosphate, 47
 - serum calcium imbalance and, 64, 103
- Parathyroid hormone receptor, structure of, 49
- Parathyroid hormone/PTHrP receptor, 49-50
- Parathyroid hormone-related protein
 - functions of, 50-52, 51t
 - in hypercalcemia of malignancy, 75-77, 76, 77t
 - for osteoporosis, 236t, 236-237
 - peptide processing from, 52
 - protein kinase activation by, 49-50
 - regulation of, 52, 53t
 - sources of, 50, 51t
 - structure of, 51-52
- Parathyroid surgery
 - complications of, 105-106
 - hypocalcemia after, 108-109, 109t-112t, 111
 - indications for, 104
 - preoperative localization in, 107t, 113
 - procedures in, 107
 - results of, 106t
 - types of, 105t
- Parathyroid tumors, 138t
- Parathyroidectomy
 - hypoparathyroidism after, 120, 121t
 - for renal osteodystrophy, 190-192
- Parenteral nutrition, hypercalcemia and, 72t
- Pelvis, in Paget's disease, 170, 171t
- Phenytoin, 164
- Pheochromocytoma
 - diagnosis of, 83t
 - hypercalcemia and, 72t
 - in multiple endocrine neoplasia, 138t, 143
 - treatment of, 147-148
- Phosphate, in serum, PTH secretion regulation by, 47
- Phosphate diabetes, 162
- Phosphate wasting, renal, 162-163
- Phosphaturia, oncogenic, 163
- Phosphorus
 - oral, in hypercalcemia treatment, 90
 - skeleton as reservoir for, 36
- Phosphorus abnormalities. See also *Hyperphosphatemia*; *Hypophosphatemia*.
 - signs and symptoms of, 276, 277t
 - treatment of, 277, 278t-279t
- Physical activity, in adolescence, 201-202
- Phytoestrogens, 237
- Piperazine estrone sulfate, 225
- Pituitary tumors, 138t-139t, 141
- Platelet-derived growth factor, bone formation and, 30
- Plicamycin (Mithracin)
 - for hypercalcemia, 85t, 91
 - for Paget's disease, 175
- Pneumocystis, 73t
- Premarin, 223t, 225
- Progesterin, 108. See also *Estrogen therapy*.
- Prostaglandin E
 - bone metabolism and, 30
 - in hypercalcemia of malignancy, 76, 77t
- Prostaglandin synthetase inhibitors (indomethacin), 85t
- Prostate cancer, 163
- Protein kinases A and C, 49-50
- Proteoglycans, in bone, 19t

Pseudofractures, 160
 Pseudohypoparathyroidism, 127, 128t, 129
 PTH. See *Parathyroid hormone*.
 PTHrP. See *Parathyroid hormone-related protein*.
 Pulmonary eosinophilic granuloma, 73t
 Pyridinoline, 32, 34
 as bone markers, 33

Race/ethnicity
 bone size and, 215
 osteoporosis and, 195, 197, 201

Rachitic rosary, 158

Radiation therapy, 121t

Raloxifene (Evista)
 for osteoporosis, 223t, 231-232, 236t, 247t, 248
 for primary hyperparathyroidism, 108

Renal disease
 hypercalcemia in, 73t, 81
 hyperparathyroidism and, 99, 100t
 osteoporosis and, 209

Renal failure, hypocalcemia from, 117, 119-120

Renal osteodystrophy
 adynamic, 183, 187
 components of, 183t, 191
 diagnosis of, 188, 191-192
 etiology and pathogenesis of, 183-184, 185, 186-187, 191
 extraskeletal calcification and, 185, 186
 hyperparathyroidism and, 184, 185, 186
 hyperphosphoremia and, 183, 185
 osteitis fibrosa cystica and, 184, 185, 186
 osteomalacia and, 184, 185, 187
 symptoms and signs of, 187-188, 188t, 191
 treatment of, 189t, 189-192
 clinical guidelines for, 190
 surgical, 190-192

Renal phosphate wasting, genetics of, 162-163

Renal stones. See *Nephrolithiasis*.

Renal tubular acidosis, 267

Reproductive system, vitamin D effects on, 61t

Respiratory syncytial virus, 169

Retinoic x receptor, 59

Rheumatoid arthritis, 73t

Rickets. See also *Osteomalacia*.
 clinical manifestations of, 155-156, 158, 166
 end-organ resistant, 158t
 etiology and pathogenesis of, 156, 157t, 166
 drug-related, 164
 hypophosphatasia as, 163
 hypophosphatemic disorders as, 162-163
 inherited diseases as, 166-167
 oncogenic, 163
 vitamin D abnormalities as, 160-162, 205
 laboratory findings in, 158
 pathology of, 155-156
 vitamin D-resistant, 161-162, 167
 x-ray findings in, 159-160

Risedronate (Actonel), 176t, 179

Rocaltrol. See *Calcitrol (Calcijex, Rocaltrol)*.

Rugger jersey spine, 188

Sacrum, in Paget's disease, 170, 171t

Sarcoidosis, 73t
 diagnosis of, 83t
 treatment of, 90

Schmidt's syndrome, 131

Selective estrogen receptor modulators (SERMs).
 See *Raloxifene (Evista)*.

Senile osteoporosis, 197

Sex hormone-binding globulin, 203

Siderosis, 121t

Silicone injections or implants, 73t

Sipple's syndrome, 137. See also *Multiple endocrine neoplasia*.

Skeletal manifestations, of primary hyperparathyroidism,
 99, 100t, 101, 218

Skeleton
 appendicular, cortical bone in, 16
 functions of, 15
 as reservoir for calcium, phosphorus, and magnesium, 36
 structural integrity of, 15

Skelid (tiludronate), 176t, 178

Skull, in Paget's disease, 170, 171t

Smoking, osteoporosis and, 208

Sodium fluoride, osteomalacia and, 164

Spinal fracture, 195-196
 Spine
 in Paget's disease, 170, 171t
 rugger jersey, 188
 Steatorrhea, 127t
 Stem cell factor, osteoclast precursors and, 23
 Steroids, for osteoporosis, 237
 Sunlight exposure
 osteoporosis and, 205
 vitamin D disorders and, 158t
 Systemic lupus erythematosus, 73t

Tamoxifen, 232
 hypercalcemia and, 72t
 Tartrate-resistant acid phosphatase, as resorption marker, 33-34
 Testosterone, osteoporosis and, 203-204
 Tetany
 in hypocalcemia, 117
 in hypoparathyroidism, 121t
 Tetracycline
 in diagnosis of osteomalacia and rickets, 155-156
 toxicity of, 164
 TGF. See *Transforming growth factor entries*.
 Theophylline, 72t
 Thiazide diuretics
 contraindications to, 108
 hypercalcemia and, 72t, 78-79
 osteoporosis and, 209
 Thyroid C cells, calcium sensor regulation of, 45
 Thyroid carcinoma, medullary. See *Medullary thyroid carcinoma*.
 Thyroid hormones, calcium metabolism and, 63
 Thyroid hormones, osteoporosis and, 209
 Thyroidectomy, hypoparathyroidism after, 120, 121t
 Thyroiditis, 127t
 Thyrotoxicosis, 73t
 in hypercalcemia, 83t
 Tiludronate (Skelid), 176t, 178
 TNFs. See *Tumor necrosis factors*.
 Tooth loss, in osteoporosis, 211
 Trabecular bone. See *Bone, trabecular*.

Transforming growth factor-alpha (TGF-a) bone formation and, 30
 Transforming growth factor-beta (TGF-b) 17, 20t
 bone resorption and, 30
 in hypercalcemia of malignancy, 76, 77, 77t
 osteoclast precursors and, 23
 osteoporosis and, 207
 Trousseau's sign, 112t, 117, 118t, 133
 T-scores
 definition of, 216
 in osteoporosis, 195-196, 196t
 Tuberculosis, 73t
 Tumor markers, 54
 Tumor necrosis factors
 bone resorption and, 30
 in hypercalcemia of malignancy, 76, 76, 77t

Venous stasis, 72t
 Ventricular arrhythmia, 91
 Vertebral fracture, 210t, 210-211, 224
 Vipoma, 72t
 Vitamin A, 72t, 80
 Vitamin D. See also *1,25-Dihydroxyvitamin D*.
 action mechanism of, 59
 bone effects of, 62
 deficiency of, aging and, 205-206, 235-236
 dietary
 in adolescence, 201
 daily recommendations for, 206, 206t
 osteoporosis and, 204-206, 235-236, 248
 hypercalcemia from, 72t, 80, 165
 in hypercalcemia of malignancy, 76
 intestinal calcium absorption and, 59, 62
 intoxication from, 126
 metabolic activation of, 55, 58t, 58-59, 60
 mineral metabolism and, 61t, 62
 normal serum concentration of, 55
 peripheral resistance to, 161
 in primary hyperparathyroidism, 103
 proteins induced by, 63t
 requirements for, 59
 serum calcium imbalance and, 64

Vitamin D (*continued*)
target cell/tissue effects of, 61t
therapeutic
dosages of, 132, 134, 165
for hypoparathyroidism, 122, 124-126
preparations of, 122, 123t, 124
for renal osteodystrophy, 189t, 189-190, 192

Vitamin D disorders
abnormal metabolism as, 161
causes of, 156, 157t-158t
deficiency as, 160-161
malabsorption as, 162
organs involved in, 158t
osteomalacia and rickets from, 156, 157t, 160-162, 205
osteoporosis and, 204
peripheral vitamin D resistance as, 161-162

Vitamin D receptor abnormalities, rickets in, 157t

Vitamin D-resistant rickets, 161-162, 167

Vitiligo, 127t

Waldenstrom's syndrome, 72t

Wegener's granulomatosis, 73t

Werner's syndrome, 137. See also *Multiple endocrine neoplasia*.

William's syndrome, 73t

Wilson disease, 121t

Wolf's law, 22

WR-2721 (Ethiofos), 85t

Wrist fracture, 195-196, 210, 210t

X-linked hypophosphatemia, 157t

Zoledronate, 87

Zollinger-Ellison syndrome
diagnosis of, 83t
differential diagnosis of, 101
primary hyperparathyroidism in, 72t, 78

Z-score, 216

